Cargando…
Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial Cancer
This cohort study compares the proportion of patients with urothelual cancer who initiated first-line chemotherapy and immune checkpoint inhibitors during the periods before and after avelumab approval.
Autores principales: | Mamtani, Ronac, Zhang, Hanxi, Parikh, Ravi B., Patel, Khilna, Li, Haojie, Imai, Kentaro, Hubbard, Rebecca A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105303/ https://www.ncbi.nlm.nih.gov/pubmed/37058309 http://dx.doi.org/10.1001/jamanetworkopen.2023.8395 |
Ejemplares similares
-
Impact of Label Restriction on Checkpoint-Inhibitor Use in Bladder Cancer and Changes in Mortality
por: Vader, Daniel T, et al.
Publicado: (2022) -
Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval
por: Parikh, Ravi B., et al.
Publicado: (2023) -
Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma
por: Doshi, Gurjyot K., et al.
Publicado: (2023) -
Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real‐World Practice
por: Parikh, Ravi B., et al.
Publicado: (2019) -
Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone
por: Marar, Mallika, et al.
Publicado: (2022)